Position in LYEL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$45,622,626
-$19,515,443 QoQ
Shares Held
3,247,162
0.0% QoQ
Ownership
13.3%
of shares outstanding
% of Portfolio
4.15%
of 13F equity value
Holder Rank
#1
of 87 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ARCH Venture Management, LLC holds $1,092,140,745 across 11 Biotechnology names. LYEL ranks #8 (4.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PBLS |
Parabilis Medicines, Inc.
|
6,412,780 | $175,517,788 | |
| 2 | BEAM |
Beam Therapeutics Inc.
|
4,540,132 | $155,817,330 | |
| 3 | RAPP |
Rapport Therapeutics, Inc.
|
3,728,738 | $155,376,512 | |
| 4 | SPTX |
Seaport Therapeutics, Inc.
|
6,294,951 | $136,726,335 | |
| 5 | ERAS |
Erasca, Inc.
|
7,091,557 | $129,917,324 | |
| 6 | VIR |
Vir Biotechnology, Inc.
|
12,694,163 | $129,353,520 | |
| 7 | MAZE |
Maze Therapeutics, Inc.
|
4,120,053 | $122,942,381 | |
| 8 | LYEL |
Lyell Immunopharma, Inc.
This page
|
3,247,162 | $45,622,626 |
All Filings in LYEL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $45,622,626 | 3,247,162 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $65,138,069 | 3,247,162 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $84,924,236 | 2,759,072 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $44,807,329 | 2,759,072 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $16,094,404 | 1,820,634 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||